Research programme: cannabinoid-based therapeutics - Revive Therapeutics

Drug Profile

Research programme: cannabinoid-based therapeutics - Revive Therapeutics

Alternative Names: REV 100; REV 101; REV 200; REV 201

Latest Information Update: 14 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Revive Therapeutics
  • Developer Revive Therapeutics; University of Wisconsin-Madison
  • Class Analgesics; Anti-inflammatories; Cannabinoids; Hepatoprotectants; Skin disorder therapies; Small molecules
  • Mechanism of Action Cannabinoid receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Skin disorders
  • Research Kidney disorders; Liver disorders; Neuropathic pain

Most Recent Events

  • 11 Oct 2017 Preclinical trials in Skin disorders in Canada (Topical)
  • 11 Oct 2017 Preclinical pharmacodynamics data in inflammatory Skin disorders released by Revive Therapeutics
  • 27 Sep 2017 Revive Therapeutics submits application to the USFDA seeking orphan drug designation for cannabidiol for the treatment of autoimmune hepatitis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top